Pelvic Health Electrically Evoked Recording (PEER) 2 Study
MedtronicNeuro · NCT05200923
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 300
- US sites recruiting
- 5
- Study start
- January 18, 2022
- Record last updated
- October 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
To collect physiological signals at several timepoints during the therapy evaluation period.
Being studied: Sacral Neuromodulation
Conditions: Overactive Bladder; Fecal Incontinence; Urinary Retention
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Overactive Bladder Criteria Inclusion Criteria
- 18 years of age or older
- Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
- Willing and able to provide signed and dated informed consent
- Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
- Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation
- For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.
- For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary.
Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.
Non-Obstructive Urinary Retention Inclusion Criteria
- 18 years of age or older
- Candidate for or undergoing Medtronic InterStim lead implant for labeled indication* requiring an advanced evaluation
- Willing and able to provide signed and dated informed consent
- Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
- Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation
- Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions.
Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.
Fecal Incontinence Inclusion Criteria
- 18 years of age or older
- Candidate for or undergoing Medtronic InterStim lead implant labeled indication* requiring an advanced evaluation
- Willing and able to provide signed and dated informed consent
- Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
- Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation
- Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling)
Note*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.
Exclusion Criteria
Overactive Bladder Criteria Exclusion Criteria
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
- Implanted with a neurostimulator, pacemaker or defibrillator
- Pelvic floor muscle dysfunction due to surgical intervention or injury
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
- History of diabetes unless the diabetes is well-controlled through diet and/or medications
- Have symptomatic urinary tract infection (UTI)
- Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
- Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
- Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
- Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
- Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
- Women who are pregnant or planning to become pregnant
- Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Non-Obstructive Urinary Retention Exclusion Criteria
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
- Implanted with a neurostimulator, pacemaker or defibrillator
- Pelvic floor muscle dysfunction due to surgical intervention or injury
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
- History of diabetes unless the diabetes is well-controlled through diet and/or medications
- Have symptomatic urinary tract infection (UTI)
- Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
- Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
- Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
- Women who are pregnant or planning to become pregnant
- Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Fecal Incontinence Exclusion Criteria
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
- Implanted with a neurostimulator, pacemaker or defibrillator
- Pelvic floor muscle dysfunction due to surgical intervention or injury
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
- Have uncorrected high grade internal rectal prolapse
- Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
- Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
- Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
- Women who are pregnant or planning to become pregnant
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Recruiting US locations
Indiana University Health Methodist Research Institute
Indianapolis, IN 46202
Site contact: Andi Nowakowski · 317-278-6752 · amnowako@iu.edu
Ochsner Clinic Foundation
New Orleans, LA 70121
Site contact: Samantha Ahrens · 504-842-2455 · samantha.ahrens@ochsner.org
Mayo Clinic Urology/Urogynecology Department
Rochester, MN 55905
Site contact: Stacy Wroblewski · 507-422-3984 · wroblewski.stacy@mayo.edu
University Hospitals Cleveland Medical Center
Cleveland, OH 44106
Site contact: Paul Cinicola · 216-286-7376 · paul.cinicola@uhhospitals.org
OhioHealth Physician's Group Urology
Hilliard, OH 43026-2050
Site contact: Diamond Rapp · 740-375-2490 · Diamond.Rapp@ohiohealth.com
Study contacts (from the official record)
- Katherine Peterson · 414-704-4065 · katherine.r.peterson@medtronic.com
Similar studies in Indiana
All women’s health studies in Indiana →- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Pfizer
- Location
- Evansville, IN + 30 other US sites
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingHealthy volunteers
Prebiotics (Dried Plum) and Immune Function in Postmenopausal Women
Indiana University
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 60–75 · Women only